Champions Oncology, Inc.

CSBR

US15870P3073

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
4.7 ^USD	-0.63%		-2.69%	-16.37%

Mar. 15	Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	CI
Mar. 13	Craig-Hallum Downgrades Champions Oncology to Hold From Buy	MT

Champions Oncology, Inc. Provides Revenue Guidance for the Fiscal Year 2022

July 22, 2021 at 08:30 am EDT

Champions Oncology, Inc. provided revenue guidance for the fiscal year 2022. The company forecast revenue growth of 10% - 20% in 2022.

Latest news about Champions Oncology, Inc.

Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	Mar. 15	CI
Craig-Hallum Downgrades Champions Oncology to Hold From Buy	Mar. 13	MT
Champions Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 12	CI
Transcript : Champions Oncology, Inc., Q3 2024 Earnings Call, Mar 12, 2024	Mar. 12
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	Dec. 13	CI
Craig Hallum Trims Champions Oncology Price target to $9 From $10, Maintains Buy Rating	Dec. 13	MT
Transcript : Champions Oncology, Inc., Q2 2024 Earnings Call, Dec 12, 2023	Dec. 12
Champions Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Dec. 12	CI
MORNING BID AMERICAS-Disinflation station	Dec. 12	RE
North American Morning Briefing : Traders Eye -2-	Dec. 12	DJ
Champions Oncology, Inc. Appoints Brady Davis as President	23-10-17	CI
Roth MKM Adjusts Price Target on Champions Oncology to $7.50 From $9, Maintains Buy Rating	23-09-22	MT
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	23-09-13	CI
Transcript : Champions Oncology, Inc., Q1 2024 Earnings Call, Sep 13, 2023	23-09-13
Champions Oncology, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-13	CI
Champions Oncology Enters Multiyear Deal With BioVolume to Better Evaluate Cancer Studies	23-08-01	MT
Champions Oncology, Inc. Announces Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies	23-08-01	CI
Transcript : Champions Oncology, Inc., Q4 2023 Earnings Call, Jul 24, 2023	23-07-24
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	23-07-24	CI
Champions Oncology, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	23-07-24	CI
Champions Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended April 30, 2023	23-07-24	CI
Champions Oncology Forms Therapeutic Discovery Platform Unit Corellia AI	23-04-17	MT
Champions Oncology, Inc. announces an Equity Buyback for $5 million worth of its shares.	23-04-05	CI
Champions Oncology, Inc. authorizes a Buyback Plan.	23-03-28	CI
Benchmark Company Downgrades Champions Oncology to Hold From Speculative Buy	23-03-16	MT

Chart Champions Oncology, Inc.

Duration

Period

More charts

Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Companyâs TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.

Sector

Biotechnology & Medical Research

Calendar

2024-07-17 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.7 USD

Average target price

6 USD

Spread / Average Target

+27.66%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CHAMPIONS ONCOLOGY, INC.	-16.37%	63.89M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research